Terms: = Pancreatic cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
30 results:
1. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract] [Full Text] [Related]
2. Expression of miR-425-5p in pancreatic Carcinoma and Its Correlation with Tumor Immune Microenvironment.
Jian S; Kong D; Tian J
J Invest Surg; 2023 Dec; 36(1):2216756. PubMed ID: 37455016
[No Abstract] [Full Text] [Related]
3. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
[TBL] [Abstract] [Full Text] [Related]
4. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract] [Full Text] [Related]
5. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract] [Full Text] [Related]
6. Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
[TBL] [Abstract] [Full Text] [Related]
7. Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of il2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma.
Ahmed A; Köhler S; Klotz R; Giese N; Lasitschka F; Hackert T; Springfeld C; Zörnig I; Jäger D; Halama N
Oncoimmunology; 2021; 10(1):1962135. PubMed ID: 34408923
[TBL] [Abstract] [Full Text] [Related]
8. Fibroblasts as a Biological Marker for Curative Resection in pancreatic Ductal Adenocarcinoma.
Katsuta E; Rashid OM; Takabe K
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485981
[TBL] [Abstract] [Full Text] [Related]
9. Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms.
Herman Mahečić D; Cigrovski Berković M; Zjačić-Rotkvić V; Čačev T; Kapitanović S; Ulamec M
Bosn J Basic Med Sci; 2020 Nov; 20(4):445-450. PubMed ID: 32156252
[TBL] [Abstract] [Full Text] [Related]
10. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer.
Feng L; Qi Q; Wang P; Chen H; Chen Z; Meng Z; Liu L
J Int Med Res; 2018 Dec; 46(12):5228-5236. PubMed ID: 30304975
[TBL] [Abstract] [Full Text] [Related]
11. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma.
Yang C; Cheng H; Zhang Y; Fan K; Luo G; Fan Z; Huang Q; Lu Y; Jin K; Wang Z; Yu X; Liu C
Cancer Immunol Immunother; 2018 Dec; 67(12):1815-1823. PubMed ID: 30167864
[TBL] [Abstract] [Full Text] [Related]
12. Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer.
Liu Z; Poiret T; Meng Q; Rao M; von Landenberg A; Schoutrop E; Valentini D; Dodoo E; Peredo-Harvey I; Maeurer M
J Transl Med; 2018 Jul; 16(1):182. PubMed ID: 29970101
[TBL] [Abstract] [Full Text] [Related]
13. Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.
Yan X; Jiao SC; Zhang GQ; Guan Y; Wang JL
Cancer Gene Ther; 2017 Feb; 24(2):57-63. PubMed ID: 28084319
[TBL] [Abstract] [Full Text] [Related]
14. Inducing a humoral immune response to pancreatic cancer antigen.
Seifert M; Seifert G; Wolff-Vorbeck G; Langenmair E; Hopt UT; Wittel UA
Cell Immunol; 2016 Dec; 310():150-155. PubMed ID: 27663207
[TBL] [Abstract] [Full Text] [Related]
15. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy.
Li X; Xu JX
J Theor Biol; 2016 Oct; 406():42-51. PubMed ID: 27338302
[TBL] [Abstract] [Full Text] [Related]
16. Cytokines as Biomarkers of pancreatic Ductal Adenocarcinoma: A Systematic Review.
Yako YY; Kruger D; Smith M; Brand M
PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Karakhanova S; Ryschich E; Mosl B; Harig S; Jäger D; Schmidt J; Hartwig W; Werner J; Bazhin AV
Br J Cancer; 2015 Mar; 112(6):1027-36. PubMed ID: 25742476
[TBL] [Abstract] [Full Text] [Related]
18. Research on the epigenetic modification of pancreatic cancer vaccine.
Cao W; Zhou G; Qiu J; Xu L; Ding X; Zhang H; Zhou X
Hepatogastroenterology; 2014; 61(130):272-7. PubMed ID: 24901123
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetically modified pancreatic carcinoma PANC-1 cells can act as cancer vaccine to enhance antitumor immune response in mice.
Tao Y; Lin F; Li T; Xie J; Shen C; Zhu Z
Oncol Res; 2013; 21(6):307-16. PubMed ID: 25198660
[TBL] [Abstract] [Full Text] [Related]
20. Effect of high-dose intravenous vitamin C on inflammation in cancer patients.
Mikirova N; Casciari J; Rogers A; Taylor P
J Transl Med; 2012 Sep; 10():189. PubMed ID: 22963460
[TBL] [Abstract] [Full Text] [Related]
[Next]
